Showing 1 - 10 of 10
Persistent link: https://www.econbiz.de/10011542427
Persistent link: https://www.econbiz.de/10011542430
Persistent link: https://www.econbiz.de/10011575676
Persistent link: https://www.econbiz.de/10011575679
Persistent link: https://www.econbiz.de/10012220983
Persistent link: https://www.econbiz.de/10011947254
The Value of a Statistical Life (VSL) is a widely used measure of the value of mortality risk reduction. Since VSL should reflect preferences and attitudes to risk, there are reasons to believe that it varies depending on the type of risk involved. It has been argued that cancer should be...
Persistent link: https://www.econbiz.de/10013208765
For the assessment of value of new therapies in healthcare, Health Technology Assessment (HTA) agencies often review the cost per Quality-Adjusted Life-Years (QALY) gained. Some HTAs accept a higher cost per QALY gained when treatment is aimed at prolonging survival for patients with a short...
Persistent link: https://www.econbiz.de/10013208766
The value of a Quality-Adjusted Life-Year (QALY) and the Value of a Statistical Injury (VSI) are important measures within health economics and transport economics. Several studies have therefore estimated people's WTP for these estimates, but most results show problems with scale insensitivity....
Persistent link: https://www.econbiz.de/10013208776
To decide how much resources to spend on reducing mortality risk, governmental agencies in several countries turn to the value of a statistical life (VSL). VSL has been shown to vary depending on the size of the risk reduction, which indicates that WTP does not increase near-proportional in...
Persistent link: https://www.econbiz.de/10013208777